NKTRNektar Therapeutics

$41.14-25% 1Y

$41.14

$35.1252 weeks$100.35

NKTR in its own filings

NKTR's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

560

Events found in the filings · across 1,979 filings · the record starts in 1996

Hard flags: 2
Hard flags
Most recent filing: Oct 1, 2026
Most recent filing · Form 8-K
Record starts: Aug 14, 1996
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 5, 2026
Restatement admitted (non-reliance)historical: 2005-03-01
Delisting notice / listing-rule failure3 occurrences: 2025-04-04
Material impairmenthistorical: 2022-05-02
SEC comment-letter activity26 occurrences: 2025-03-28

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 1, 2026Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026.Regulation FD disclosure · press release
Sep 25, 2026In August 2023, Nektar Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California (the “District Court”) against Eli Lilly and Company (“Lilly”) alleging, among other claims, breach of contract and breach of the implied covenant of good faith and fair dealing in …Other event · Form 8-K
Aug 13, 2026Nektar Therapeutics Announces Second Quarter.Earnings release · press release
May 8, 2026On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares …Material agreement entered · Form 8-K
May 7, 2026Therapeutics Reports First Quarter 2026 Financial Results.Earnings release · press release
Apr 23, 2026On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”) …Material agreement entered · Form 8-K
Apr 20, 2026Phase 2b REZOLVE-AA Results – Blinded 16-Week Treatment Extension Period On April 20, 2026, the Company announced 52-week topline results from the blinded 16-week treatment extension period of its REZOLVE-AA study of rezpegaldesleukin.Regulation FD disclosure · Form 8-K
Mar 12, 2026Nektar Therapeutics Reports Fourth Quarter and.Earnings release · press release
Feb 13, 2026On February 11, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the …Material agreement entered · Form 8-K